EXPLORE!

DiabetesIndia 2022: Cardio-Renal Metabolic Disorder, is the Panacea Available Now?

  489 Views

#Diabetes and Endocrinology  #Multispeciality 

Dr Mangesh Tiwaskar, Mumbai    27 June 2022

“It should be the function of medicine to have people die young as late as possible.”

        —Ernest L Wynder

  • Diabetes treatment for CVD reduction is categorized in two arms, i.e., SGLT2 inhibitors and GLP-1R antagonists with hemodynamic effect and anti-atherogenic effect mechanism of action respectively.
  • SGLT2 inhibitors improve ventricular loading conditions (diuresis, natriuresis, etc.), myocardial energetics, TGF, IGH, etc. by modulating SNS activity.
  • GLP-1R on the other hand has anti-inflammatory effects, reduces oxidative stress, inhibits RAAS, increases natriuresis, etc.
  • SGLT2 inhibitors and GLP-1R provide complete CV renal protection combined and are a challenge.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.